Founded in February 2024 and registered in the China (Shanghai) Pilot Free Trade Zone, Skye Medicine is an innovative biotech enterprise focusing on the development of next‑generation, potent and accessible multi‑target cellular immunotherapies.
Headquartered in Zhangjiang Science City, Shanghai, the company houses Grade C clean laboratories and BSL‑2 (P2) biosafety laboratories. It has established subsidiaries in Suzhou and Chengdu, forming an operational system covering R&D, manufacturing and regional collaboration.
Skye Medicine addresses the core unmet medical needs in cell immunotherapy. It relies on four self‑developed technology platforms:
- LVV-based Fully-human 4th Generation Dual-targeting In vivo CAR Platform
- cssDNA-LNP based Fully-human 4th Generation Dual-targeting In vivo CAR Platform
- Fully-human Dual targeting Universal CAR Platform
- Fully-human Dual targeting 4th Generation QuickCAR Platform
The company strives to break key bottlenecks of current cell immunotherapies in terms of accessibility, in vivo persistence and manufacturing processes, and develops innovative therapies with clinical value for patients with cancer and autoimmune diseases.
To Become the Leader in Cell and Gene Therapy
Bring The Benefits of Innovation to Patients and Create Sustainable Value for Investors, Employees, and Society
• Innovation
• Tenacity
• Do what's right
Company officially incorporated in the Shanghai Free Trade Zone
Initiated the Skye-03 In Vivo CAR-T Program
Completed core sequence screening and in vitro functional validation for Skye-01 candidate
Received first tranche of USD seed financing
Completed core sequence screening and in vitro functional validation for Skye-02 candidate
Closed RMB 120 million seed financing round
Initiated the Skye-04 In Vivo CAR-T Program
Established Quality Management System (QMS)
Built clinical team and advanced candidates to IIT / IND clinical application stage
